Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2025)

Historic Gross Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 53.46%.

  • Insight Molecular Diagnostics' Gross Margin rose 99800.0% to 53.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.73%, marking a year-over-year increase of 507800.0%. This contributed to the annual value of 39.34% for FY2024, which is 118600.0% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Gross Margin of 53.46% as of Q3 2025, which was up 99800.0% from 67.57% recorded in Q2 2025.
  • Insight Molecular Diagnostics' Gross Margin's 5-year high stood at 72.47% during Q4 2021, with a 5-year trough of 401.49% in Q3 2022.
  • In the last 5 years, Insight Molecular Diagnostics' Gross Margin had a median value of 25.57% in 2024 and averaged 2.15%.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Gross Margin skyrocketed by 92195300bps in 2021, and later tumbled by -3134800bps in 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' Gross Margin (Quarter) stood at 72.47% in 2021, then crashed by -114bps to 9.85% in 2022, then tumbled by -278bps to 37.26% in 2023, then soared by 207bps to 40.04% in 2024, then surged by 34bps to 53.46% in 2025.
  • Its Gross Margin was 53.46% in Q3 2025, compared to 67.57% in Q2 2025 and 61.97% in Q1 2025.